Evaluation of anti α-d-Glcp-(1→4)-α-d-Glcp (GAGA4) IgM antibodies as a biomarker for multiple sclerosis. Issue 49 (6th August 2018)

• Record Type: Journal Article
• Authors: Braganza, Chriselle D.; Santoso, Kristiana T.; Dangerfield, Emma M.; La Flamme, Anne C.; Timmer, Mattie S. M.; Stocker, Bridget L.
• Is Part Of: RSC advances. Volume 8:Issue 49(2018)
• Page Start: 28086
• Page End: 28093
• Publication Date: 2018-08-06
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c8ra04897e
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Anti-glucose IgM antibodies are not upregulated in RRMS patients and thus are not a suitable biomarker for MS. Abstract : The correct diagnosis of multiple sclerosis (MS) remains challenging due to the complex pathophysiological and clinical characteristics of the disease. Consequently, there has been immense interest in finding a non-invasive diagnostic test for MS. Recent studies found that serum anti-α-d -Glc p -(1→4)-α-d -Glc p (GAGA4) IgM antibodies were upregulated in MS patients, and this finding led to the development of a commercial diagnostic test (gMS® Dx test), although the test has poor selectivity and has not been independently validated. Herein, we developed an enzyme-linked immunosorbent assay (ELISA) to evaluate the use and reliability of several anti-glucose IgM antibodies, including those against GAGA4, as diagnostic biomarkers for MS. In contrast to previous studies, our results show that serum anti-GAGA4 IgM antibody levels are not significantly higher in MS patients, which could potentially explain the poor selectivity of the commercial test.